Owls Nest Partners Acquires New Position in CorVel
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Fool
- New Position Disclosure: On May 14, 2026, Owls Nest Partners IA disclosed a new holding of 348,329 shares of CorVel (CRVL), with an estimated transaction value of $20.06 million, reflecting confidence in the company's potential.
- Asset Management Significance: CorVel now accounts for 6.66% of Owls Nest's reportable AUM, indicating its growing importance in the investment portfolio, which may influence future investment strategies.
- Financial Performance: CorVel's fiscal 2026 revenue rose by 7% to $959 million, while diluted earnings per share increased by 17% to $2.14, demonstrating the company's ability to grow even in challenging market conditions, attracting investor interest.
- Market Outlook: Despite a 45% decline in stock price, CorVel has secured several large clients for its healthcare payment accuracy platform, CERIS, which is expected to enhance future revenue visibility, underscoring the company's competitiveness in healthcare cost management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRVL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRVL
About CRVL
CorVel Corporation applies technology, including artificial intelligence, machine learning and natural language processing, to enhance the management of episodes of care and the related health-care costs. The Company partners with employers, third-party administrators, insurance companies and government agencies to assist its customers in managing the medical costs of workers compensation, group health and auto insurance, and in monitoring the quality of care provided to claimants. Its services include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care and Medicare services. It delivers its solutions in three ways - as a fully integrated claims-management program, as discrete standalone services, or as targeted add-ons that enhance an existing client workflow. Integrated, end-to-end bundled programs are designed primarily for buyers such as self-insured employers who want a single, turnkey partner.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- New Position Disclosure: On May 14, 2026, Owls Nest Partners IA disclosed a new holding of 348,329 shares of CorVel (CRVL), with an estimated transaction value of $20.06 million, reflecting confidence in the company's potential.
- Asset Management Significance: CorVel now accounts for 6.66% of Owls Nest's reportable AUM, indicating its growing importance in the investment portfolio, which may influence future investment strategies.
- Financial Performance: CorVel's fiscal 2026 revenue rose by 7% to $959 million, while diluted earnings per share increased by 17% to $2.14, demonstrating the company's ability to grow even in challenging market conditions, attracting investor interest.
- Market Outlook: Despite a 45% decline in stock price, CorVel has secured several large clients for its healthcare payment accuracy platform, CERIS, which is expected to enhance future revenue visibility, underscoring the company's competitiveness in healthcare cost management.
See More
- Share Acquisition: Owls Nest acquired 348,329 shares of CorVel in Q1 2026, with an estimated trade value of $20.06 million, indicating confidence in the company despite recent stock declines.
- AUM Growth: This transaction resulted in a 7.02% increase in Owls Nest's 13F reportable AUM, reflecting the effectiveness of its investment strategy in the healthcare management sector.
- Financial Performance: CorVel reported a 7% revenue increase to $959 million for fiscal 2026, with diluted earnings per share rising 17%, showcasing strong performance in the insurance and risk management space.
- Market Outlook: Growing demand for CorVel's healthcare payment accuracy platform, CERIS, is expected to provide greater revenue visibility, indicating that the company's strategic focus on innovation and operational efficiency is beginning to pay off.
See More
- Quarterly Revenue Growth: CorVel's revenue for the March quarter reached $249 million, marking a 7% increase from $232 million in the same period last year, indicating strong market performance and reinforcing its industry position.
- Earnings Per Share Increase: The quarterly EPS rose from $0.51 to $0.61, a 19.6% increase, reflecting a significant enhancement in profitability that may attract more investor interest.
- Annual Net Income Growth: The net income for FY 2026 was $110 million, a 14% increase over FY 2025, demonstrating the company's success in cost control and efficiency improvements, thereby enhancing its future growth potential.
- Share Repurchase Program: CorVel repurchased 872,744 shares at a cost of $56 million during FY 2026, showcasing confidence in its own value while also providing additional returns to shareholders.
See More
- Significant Revenue Growth: CorVel's Q4 fiscal 2026 revenue reached $249 million, a 7% increase year-over-year, indicating robust market performance that is expected to further enhance future profitability.
- Earnings Per Share Increase: The earnings per share for the fourth quarter was $0.61, up 19.6% from $0.51 in the same period last year, reflecting improved profitability that may attract more investor interest.
- Surge in New Bookings: New bookings increased by 56% year-over-year, with RFP activity rising by 20%, indicating strong momentum in market demand that is expected to significantly support revenue growth in the second half of the year.
- Strategic Investment and Risk Management: CorVel's ongoing investments in AI and automation aim to enhance operational efficiency, while management highlighted risks related to cybersecurity and rising medical costs, demonstrating a commitment to growth alongside risk control and sustainable development.
See More
- Earnings Highlights: CorVel reported a GAAP EPS of $0.61 for Q4, with revenue reaching $248.55 million, reflecting a 7.4% year-over-year growth that underscores the company's robust growth trajectory and boosts investor confidence.
- Cash Position: At the end of the quarter, CorVel exited with $233 million in cash and cash equivalents, with no borrowings, providing a solid financial foundation for future investments and expansions.
- Stock Buyback: The company repurchased $20.1 million of common stock during the quarter, indicating management's confidence in the company's future prospects while also enhancing earnings per share and shareholder value.
- Growth Potential: With ongoing market growth and strong financial performance, CorVel is expected to continue benefiting from industry recovery and increasing market demand, further solidifying its market position.
See More










